David Mutch, MD

Medical School Department Obstetrics and Gynecology
Research Program Solid Tumor Therapeutics
David Mutch

Researcher Background

Primary Academic Title

Professor, Obstetrics and Gynecology, WashU Medicine

Training

  • 1984 - 1987: Fellow, gynecologic oncology, Duke University, Durham, N.C.
  • 1980 - 1984: Resident, obstetrics and gynecology, Washington University, St. Louis

Education

  • 1980: MD, Washington University, St. Louis

Research & Selected Publications

Research Interest

Cytokine activity against tumor cell mechanism of action; molecular genetics of endometrial and ovarian cancers; and RER mutations, LOH, cloning areas of loss on 10q and 1p. Principal Investigator, SPORE in Endometrial Cancer

Research Publications

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Authors:

Abu-Rustum NR, Campos SM, Amarnath S, one or more additional authors omitted Mutch D, one or more additional authors omitted Sambandam V

Journal & Year:

J Natl Compr Canc Netw • 2026

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Authors:

Abu-Rustum NR, Campos SM, Amarnath S, one or more additional authors omitted Mutch D, one or more additional authors omitted Sambandam V

Journal & Year:

J Natl Compr Canc Netw • 2025

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.
Authors:

Matsuo K, Enserro DM, Wright JD, one or more additional authors omitted Mutch DG

Journal & Year:

Gynecol Oncol • 2025

Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.
Authors:

Valentine MC, Mullen MM, Kotnik EN, one or more additional authors omitted Mutch DG, Fuh KC

Journal & Year:

Cancer Res • 2025

Invited Commentary: Opportunistic Salpingectomy: A Call to Implement Science Arms to Prevent Ovarian Cancer.
Authors:

Hagemann AR, Mutch DG

Journal & Year:

J Am Coll Surg • 2025

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Authors:

Abu-Rustum NR, Campos SM, Amarnath S, one or more additional authors omitted Mutch D, one or more additional authors omitted Sambandam V

Journal & Year:

J Natl Compr Canc Netw • 2025

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.
Authors:

Schab A, Compadre A, Drexler R, one or more additional authors omitted Mutch D, one or more additional authors omitted Mullen MM

Journal & Year:

J Clin Invest • 2025

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Authors:

Matei DE, Enserro DM, Randall ME, Mutch D, one or more additional authors omitted Miller DS

Journal & Year:

J Clin Oncol • 2025